Influenza, Human: all 2,264 studies

Page 22 of 23. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza VaccinesCompletedNCT00478816Phase 2
• The Effect of Rituximab on the Humoral Response to Influenza VaccineTerminatedNCT00466037Not applicable
• Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00462215Phase 3
• Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy AdultsCompletedNCT00457509Phase 1
• Influenza Vaccine in Premature InfantsCompletedNCT00455169
• REDucing Influenza Among University Students, University of California at BerkeleyCompletedNCT00448773Phase 4
• Cigarette Smoke and Susceptibility to Influenza InfectionCompletedNCT00448617
• Project to Investigate Ways to Reduce the Spread of Influenza in Schools and Households With ChildrenCompletedNCT00446628Not applicable
• Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) StatusCompletedNCT00442975Phase 4
• A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for InfluenzaCompletedNCT00440362Phase 1/2
• A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.TerminatedNCT00436124Phase 4
• Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly SubjectsCompletedNCT00434733Phase 3
• Clinical IGSP-CHOP BostonCompletedNCT00428831
• China Case Control Avian InfluenzaCompletedNCT00428753
• Prospective Study of AI H5N1 in ChinaCompletedNCT00428493
• A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in HouseholdsCompletedNCT00425893Not applicable
• Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)CompletedNCT00424086Phase 1/2
• Pilot Study of Genotypic AnalysisCompletedNCT00421837
• Inpatient Influenza SurveillanceCompletedNCT00419861
• Influenza Vaccination in Bone Marrow TransplantationCompletedNCT00419224Phase 4
• Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 VirusesWithdrawnNCT00417560Not applicable
• Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the ElderlyCompletedNCT00415129Phase 2
• A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.CompletedNCT00412555Phase 4
• A Randomized, Controlled, Unblinded, Clinical Trial of the Acceptability and Efficacy of Non-Pharmaceutical Methods in Preventing Spread of Influenza Within the FamilyStatus unknownNCT00410176Not applicable
• Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in ChildrenCompletedNCT00408395Phase 2
• Safety Study of Avian Flu VaccineCompletedNCT00408109Phase 1
• Improving Influenza Vaccination Rates Among Health Care ProfessionalsCompletedNCT00404664Not applicable
• Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal StrategyCompletedNCT00402805Phase 4
• Influenza Vaccine Postpartum QuestionnaireCompletedNCT00401700
• Th1 Response to Influenza: Aging and Vaccine EfficacyTerminatedNCT00396305Phase 4
• Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly AdultsCompletedNCT00395174Phase 3
• Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly AdultsCompletedNCT00386698Phase 2
• Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old ChildrenCompletedNCT00386542Phase 1/2
• Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in ElderlyCompletedNCT00386113Phase 2
• Proteomic Profiling for Influenza Vaccination - FluMistCompletedNCT00385281Phase 4
• Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in AdultsCompletedNCT00383539Phase 3
• Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the ElderlyCompletedNCT00383526Phase 3
• Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in AdultsCompletedNCT00382980Phase 1
• Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in AdultsCompletedNCT00382187Phase 2
• Offering Influenza and Pneumococcal Vaccine to Patients Being Evaluated in the Emergency DepartmentStatus unknownNCT00380679Phase 2
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study B)CompletedNCT00380237Phase 1
• Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older AdultsCompletedNCT00380211Phase 3
• Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult PopulationCompletedNCT00377585Phase 2
• Study of a Pandemic Influenza Vaccine in Elderly ParticipantsCompletedNCT00376402Phase 2
• A Safety and Immunology Study of a DNA Trivalent Influenza VaccineCompletedNCT00375206Phase 1
• Efficacy of Sambucol in the Treatment of InfluenzaCompletedNCT00375115Phase 4
• Influenza Vaccination in Prevention From Acute Coronary Events in Coronary Artery Disease - FLUCAD StudyCompletedNCT00371098Phase 2/3
• Study of a Pandemic Influenza Vaccine in ChildrenCompletedNCT00370864Phase 2
• A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in AdultsCompletedNCT00363870Phase 4
• Influenza Vaccination of Nursing Home Workers.TerminatedNCT00359554Not applicable
• Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy SubjectsCompletedNCT00356798Phase 1
• Safety and Immunogenicity of Preservative Free Inactivated Split Influenza Vaccine, Using the Strain Composition 2006/2007 in Non-Elderly Adult and Elderly SubjectsCompletedNCT00354016Phase 3
• Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00349141Phase 1/2
• Study of the Ability of a Flu Vaccine to Prevent Flu InfectionCompletedNCT00349037Phase 1
• Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy AdultsCompletedNCT00347672Phase 1
• Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of FluCompletedNCT00347529Phase 1
• Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.CompletedNCT00346723Phase 3
• Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006/2007 in Adults Aged 18 Years or AboveCompletedNCT00345904Phase 3
• Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.WithdrawnNCT00345462Phase 3
• A Study of the Immunogenicity and Safety of the 2006-2007 Influenza VaccineCompletedNCT00343681Phase 2
• Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or OlderWithdrawnNCT00342940Phase 2
• T and B Cell Response to Avian Flu VaccineCompletedNCT00337896
• Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy PediatricsCompletedNCT00336453Phase 1/2
• Pharma-Pen (Formerly Innoject) Auto-injectory TIVWithdrawnNCT00335855Phase 1
• Alternative Oseltamivir Dosing StrategiesCompletedNCT00334529Phase 2
• Immunogenicity, Safety and Tolerability of CSL Limited Inactivated Influenza Vaccine in AdultsCompletedNCT00333398Phase 3
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or OlderCompletedNCT00329966Phase 2
• Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Elderly SubjectsCompletedNCT00329927Phase 2
• Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy AdultsCompletedNCT00328107Phase 2/3
• Phase II Study of Pandemic Influenza VaccineCompletedNCT00320346Phase 2
• Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly PopulationCompletedNCT00318058Phase 1
• Safety and Immunogenicity of an Adjuvanted Influenza Vaccine in Subjects Aged 65 Years and Over.CompletedNCT00316628Phase 2
• Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.CompletedNCT00316615Phase 2
• Cell-Mediated Immune Responses to Influenza A/H5N1 VaccineCompletedNCT00311727Not applicable
• Safety, Tolerability and Pharmacokinetic Study of Biota-CS-8958CompletedNCT00311714Phase 1
• Chart Review of Antivirals for Influenza in InfantsCompletedNCT00311701
• St. Jude Open Label H5 TrialCompletedNCT00311675Phase 1/2
• Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing FacilitiesCompletedNCT00311649Phase 1/2
• Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly SubjectsCompletedNCT00311480Phase 2
• Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 MonthsCompletedNCT00311428Phase 4
• Comparative Trial Evaluating Safety and Immunogenicity of an Adjuvanted and a Conventional Influenza Vaccine in Elderly Subjects (> 60 Years)CompletedNCT00310648Phase 3
• H5N1 Vaccine Intramuscular Versus Intradermal in Healthy AdultsCompletedNCT00310206Phase 1
• Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of AgeCompletedNCT00309647Phase 1
• Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 YearsCompletedNCT00309634Phase 1
• Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's LymphomaCompletedNCT00307710Phase 2
• Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell LymphomaCompletedNCT00307177Phase 2
• Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™CompletedNCT00306982
• Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.CompletedNCT00304434Phase 4
• Safety and Dose Study of Peramivir for Influenza TreatmentCompletedNCT00297050Phase 1
• Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the ElderlyCompletedNCT00296829Phase 2
• H5 Vaccine Alone or With Adjuvant in Healthy AdultsCompletedNCT00296634Phase 1/2
• Evaluation of the Safety and Effectiveness of a Probiotic Bacterium to Boost the Immune Response to Influenza VaccinesStatus unknownNCT00294788Phase 1/2
• H5 Vaccine Alone or With Aluminum Hydroxide in Elderly AdultsCompletedNCT00294099Phase 1/2
• Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)CompletedNCT00289510Phase 1/2
• Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
• H5 Adult - Chiron Study of Bird Flu VaccineCompletedNCT00280033Phase 1/2
• The Effectiveness of Influenza Vaccine Among Health Care Workers in a Hospital Setting.CompletedNCT00265161
• TGV:Use of the Quick Diagnostic Test of the Influenza and the Infection With RSV by the Paediatric Emergency UnitCompletedNCT00263900Not applicable
• Immunogenicity Study of the Influenza Vaccine in AdultsCompletedNCT00258934Phase 2

← Influenza, Human overview